Evolent Health (EVH) to Release Quarterly Earnings on Thursday

Evolent Health (NYSE:EVH) is expected to announce its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $473.7420 million for the quarter. Individuals can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Evolent Health (NYSE:EVH) last released its earnings results on Tuesday, June 4th. The technology company reported $0.21 earnings per share for the quarter. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The business had revenue of $427.70 million during the quarter. On average, analysts expect Evolent Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolent Health Stock Up 0.5%

NYSE:EVH opened at $6.70 on Tuesday. The firm has a market cap of $787.66 million, a PE ratio of -4.16 and a beta of 0.66. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.01 and a quick ratio of 1.01. The company has a 50-day moving average of $8.45 and a 200 day moving average of $9.12. Evolent Health has a 1-year low of $6.50 and a 1-year high of $25.22.

Hedge Funds Weigh In On Evolent Health

Hedge funds have recently modified their holdings of the business. Strs Ohio purchased a new position in shares of Evolent Health during the 1st quarter worth $47,000. Headlands Technologies LLC purchased a new position in shares of Evolent Health during the 2nd quarter worth $58,000. Osaic Holdings Inc. grew its holdings in shares of Evolent Health by 99.2% during the 2nd quarter. Osaic Holdings Inc. now owns 11,119 shares of the technology company’s stock worth $125,000 after purchasing an additional 5,537 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Evolent Health by 313.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 14,202 shares of the technology company’s stock worth $160,000 after purchasing an additional 10,770 shares during the period. Finally, Vident Advisory LLC purchased a new position in shares of Evolent Health during the 2nd quarter worth $168,000.

Wall Street Analyst Weigh In

EVH has been the topic of several recent analyst reports. BTIG Research restated a “buy” rating and set a $20.00 price objective on shares of Evolent Health in a report on Tuesday, September 30th. Stephens reiterated an “equal weight” rating and issued a $9.00 target price on shares of Evolent Health in a research report on Wednesday, September 24th. Canaccord Genuity Group reiterated a “buy” rating and issued a $16.00 target price on shares of Evolent Health in a research report on Tuesday, September 9th. Truist Financial upped their target price on Evolent Health from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, July 17th. Finally, Zacks Research lowered Evolent Health from a “hold” rating to a “strong sell” rating in a research report on Friday, October 10th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $15.85.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.